Cargando…

Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension

INTRODUCTION: Macrophages are involved in development and progression of chronic liver disease and portal hypertension. The macrophage activation markers soluble (s)CD163 and soluble mannose receptor (sMR), are associated with portal hypertension in patient with liver cirrhosis but never investigate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ørntoft, Nikolaj Worm, Blé, Michel, Baiges, Anna, Ferrusquia, Jose, Hernández-Gea, Virginia, Turon, Fanny, Magaz, Marta, Møller, Søren, Møller, Holger Jon, Garcia-Pagan, Juan Carlos, Gronbaek, Henning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231705/ https://www.ncbi.nlm.nih.gov/pubmed/34177608 http://dx.doi.org/10.3389/fphys.2021.649668

Ejemplares similares

Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis
por: Gantzel, Rasmus Hvidbjerg, et al.
Publicado: (2021)

Soluble CD163 correlates with lipid metabolic adaptations in type 1 diabetes patients during ketoacidosis
por: Svart, Mads, et al.
Publicado: (2018)

Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
por: Kaji, Kosuke, et al.
Publicado: (2020)

The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study
por: Driever, Ellen G., et al.
Publicado: (2022)

Macrophage activation marker sCD163 correlates with accelerated lipolysis following LPS exposure: a human-randomised clinical trial
por: Rittig, Nikolaj, et al.
Publicado: (2017)

Nitro-oxidative stress, VEGF and MMP-9 in patients with cirrhotic and non-cirrhotic portal hypertension
por: MUTI, LEON ADRIAN, et al.
Publicado: (2015)

Management of Portal Vein Thrombosis in Cirrhotic Patients
por: Amitrano, Lucio, et al.
Publicado: (2009)

Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension
por: Biecker, Erwin
Publicado: (2013)

Causes and Management of Non-cirrhotic Portal Hypertension
por: Gioia, Stefania, et al.
Publicado: (2020)

The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients
por: Sandahl, Thomas Damgaard, et al.
Publicado: (2017)

No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial
por: Kimer, Nina, et al.
Publicado: (2018)

Wall shear stress in portal vein of cirrhotic patients with portal hypertension
por: Wei, Wei, et al.
Publicado: (2017)

Usage of Direct Acting Oral Anticoagulants in Cirrhotic and Non-Cirrhotic Portal Vein Thrombosis: A Systematic Review
por: Gupta, Sachin, et al.
Publicado: (2021)

Cardiac dysfunction in cirrhotic portal hypertension with or without ascites
por: Dadhich, Sunil, et al.
Publicado: (2014)

Idiopathic non-cirrhotic portal hypertension: a review
por: Schouten, Jeoffrey NL, et al.
Publicado: (2015)

The beneficial effects of curcumin in cirrhotic rats with portal hypertension
por: Hsu, Shao-Jung, et al.
Publicado: (2017)

Research progress on signaling pathways in cirrhotic portal hypertension
por: Xu, Wen, et al.
Publicado: (2018)

Cirrhotic portal hypertension: From pathophysiology to novel therapeutics
por: Gunarathne, Lakmie S, et al.
Publicado: (2020)

Non-cirrhotic portal hypertension in an ankylosing spondylitis patient
por: Park, Sukki, et al.
Publicado: (2018)

Non-cirrhotic portal vein thrombosis – therapeutic challenge
por: Sarquis, Lucas Mansano, et al.
Publicado: (2022)

Non-Cirrhotic Portal Hypertension in Systemic Lupus Erythematosus
por: Suárez-Díaz, Silvia, et al.
Publicado: (2023)

Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension
por: Uschner, Frank E., et al.
Publicado: (2015)

Splenic arteriovenous fistula leading to non-cirrhotic portal hypertension: a case report: Splenic arteriovenous fistula leading to non-cirrhotic portal hypertension
por: Abou Yassine, Ahmad, et al.
Publicado: (2023)

Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension
por: Kreisel, Wolfgang, et al.
Publicado: (2020)

Metastases can occur in cirrhotic livers with patent portal veins
por: Mahdi, Zaid, et al.
Publicado: (2021)

Chronic Myeloid Leukemia Presenting as Non-cirrhotic Portal Hypertension
por: Gemnani, Rinkle R, et al.
Publicado: (2023)

Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats
por: Gunarathne, Lakmie S., et al.
Publicado: (2019)

Cirrhotic Endothelial Progenitor Cells Enhance Liver Angiogenesis and Fibrosis and Aggravate Portal Hypertension in Bile Duct-Ligated Cirrhotic Rats
por: Tripathi, Dinesh Mani, et al.
Publicado: (2020)

Cirrhotic cardiomyopathy: An independent prognostic factor for cirrhotic patients
por: Lee, Yun Bin, et al.
Publicado: (2018)

The Impact of Partial Splenic Embolization on Portal Hypertensive Gastropathy in Cirrhotic Patients with Portal Hypertension
por: Saeki, Michio, et al.
Publicado: (2023)

Alcoholic Hepatitis Markedly Decreases the Capacity for Urea Synthesis
por: Glavind, Emilie, et al.
Publicado: (2016)

Cirrhotic cardiomyopathy
por: Baik, Soon Koo, et al.
Publicado: (2007)

Cirrhotic cardiomyopathy
por: Grancea-Iancu, VLM
Publicado: (2014)

Natural Course of Nonmalignant Partial Portal Vein Thrombosis in Cirrhotic Patients
por: Girleanu, Irina, et al.
Publicado: (2014)

Severe Hepatopulmonary Syndrome in an Adolescent Patient with Non-Cirrhotic Portal Fibrosis
por: Sood, Vikrant, et al.
Publicado: (2016)

Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients
por: Zhang, Zhi-Hao, et al.
Publicado: (2017)

Blood Ammonia Level Correlates with Severity of Cirrhotic Portal Hypertensive Gastropathy
por: El-Kalla, Ferial, et al.
Publicado: (2018)

Obesity is not associated with an increased risk of portal vein thrombosis in cirrhotic patients
por: Zakko, Alan, et al.
Publicado: (2018)

Systemic Mastocytosis Complicated by Non-Cirrhotic Portal Hypertension and Variceal Bleeding
por: McCarty, Thomas R., et al.
Publicado: (2017)

Laparoscopic selective esophagogastric devascularization and splenectomy for patients with cirrhotic portal hypertension
por: Lin, Jie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_frli2tse9bcs0pjcn7f3p3mg8p